Insuline spuit 0,5 ml met fijne naald (0,30 x 8 mm)Also known as: U100 insulinespuit, 0.5 ml insulin syringe with fine needle

Mechanism of Action

This product is not a peptide itself but a sterile insulin syringe intended for precise subcutaneous administration of peptide-based compounds. It allows for accurate dosage delivery of peptides by penetrating the skin and depositing the solution into subcutaneous fat tissue.

Reported Research Benefits

• Used primarily for subcutaneous injection of peptides such as BPC-157, TB-500, Ipamorelin, and other liquid compounds in laboratory and research settings. Suitable for accurate dosing especially in peptide research and treatment protocols.

Dosing Protocol & Reconstitution

Research Notes

Facilitates safe, controlled delivery of peptides in experimental or therapeutic contexts. Enables reliable subcutaneous injections necessary for peptide absorption and bioavailability studies.

Research Summary

Insuline spuit 0,5 ml met fijne naald (0,30 x 8 mm) is a medical device designed for the precise subcutaneous administration of insulin and other peptide-based therapeutics. While not a peptide itself, this insulin syringe facilitates accurate dosing critical for effective glycemic control in diabetic patients, as supported by clinical practice guidelines and numerous clinical trials on insulin delivery methods. High-quality evidence demonstrates that fine needles reduce injection pain and improve injection site tolerability, enhancing patient adherence. Limitations relate mostly to user technique and variability in patient skin and subcutaneous tissue thickness, but the device remains a standard tool for delivering peptide therapies safely and effectively.

Side Effects & Safety

As a medical device rather than a pharmacologic agent, the insulin syringe itself does not cause systemic side effects; however, improper use can lead to local skin reactions such as bruising, lipohypertrophy, or infection at the injection site. Fine needles reduce pain and tissue trauma relative to larger gauges, improving safety and patient comfort. There is no direct drug interaction, but careful syringe handling and disposal are critical to avoid needlestick injuries and cross-contamination. The device is standard in clinical practice and is not restricted by the World Anti-Doping Agency (WADA) as it is a delivery tool rather than a performance-enhancing substance.

Stability & Storage

Refer to research notes

Molecular Data

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=U100+insulinespuit+0.5+ml+insulin+syringe